NPHC · Nutra Pharma Corp · Executive Compensation
$0.00
+0.00 (+0.00%)
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of the date of the filing of this report, we do not believe that our source of cash is adequate for the next 12 months of operation and there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 19, 2026
Market Cap
$715,972
Shares
7.16B
Volume · Oct 19
928.01K
Avg daily vol (3M)
327.42K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael Flax | Chairman of the Board | Appointed | 2024-03-22 |
| Michael Flax | Chief Financial Officer | Appointed | 2024-03-22 |
| Michael Flax | Director | Appointed | 2024-03-22 |
| Michael Flax | Chief Executive Officer | Appointed | 2024-03-22 |
| Rik J. Deitsch | Chief Financial Officer | Resigned | 2024-03-22 |
| Rik J. Deitsch | Chairman of the Board | Resigned | 2024-03-22 |
| Rik J. Deitsch | Director | Resigned | 2024-03-22 |
| Rik J. Deitsch | Chief Executive Officer | Resigned | 2024-03-22 |
Leadership
- Michael Flax CEO, Chairman, CFO, Board Member